A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522534-31-00

Acronym

PB016-01-02

Enrollment

132

Registered

2025-11-13

Start date

2026-01-27

Completion date

Unknown

Last updated

2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers, Not applicable

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026